Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $64,436,400.00 in Stock

Eli Lilly and Company (NYSE:LLYGet Rating) major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $306.84, for a total transaction of $64,436,400.00. Following the completion of the transaction, the insider now directly owns 104,623,810 shares in the company, valued at $32,102,769,860.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, May 27th, Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock. The shares were sold at an average price of $318.98, for a total transaction of $63,796,000.00.
  • On Wednesday, May 25th, Lilly Endowment Inc sold 41,610 shares of Eli Lilly and stock. The shares were sold at an average price of $308.95, for a total transaction of $12,855,409.50.
  • On Monday, May 23rd, Lilly Endowment Inc sold 118,856 shares of Eli Lilly and stock. The shares were sold at an average price of $302.73, for a total transaction of $35,981,276.88.
  • On Wednesday, May 18th, Lilly Endowment Inc sold 700 shares of Eli Lilly and stock. The shares were sold at an average price of $302.00, for a total transaction of $211,400.00.
  • On Monday, May 16th, Lilly Endowment Inc sold 80,761 shares of Eli Lilly and stock. The stock was sold at an average price of $302.53, for a total transaction of $24,432,625.33.
  • On Friday, April 8th, Lilly Endowment Inc sold 139,045 shares of Eli Lilly and stock. The stock was sold at an average price of $310.79, for a total transaction of $43,213,795.55.
  • On Wednesday, April 6th, Lilly Endowment Inc sold 51,851 shares of Eli Lilly and stock. The stock was sold at an average price of $300.92, for a total transaction of $15,603,002.92.
  • On Monday, April 4th, Lilly Endowment Inc sold 39,393 shares of Eli Lilly and stock. The stock was sold at an average price of $293.15, for a total transaction of $11,548,057.95.
  • On Friday, April 1st, Lilly Endowment Inc sold 165,376 shares of Eli Lilly and stock. The stock was sold at an average price of $292.38, for a total transaction of $48,352,634.88.
  • On Wednesday, March 30th, Lilly Endowment Inc sold 2,500 shares of Eli Lilly and stock. The stock was sold at an average price of $292.03, for a total transaction of $730,075.00.

Shares of LLY stock traded up $5.26 during midday trading on Thursday, hitting $311.95. 139,536 shares of the company were exchanged, compared to its average volume of 2,977,431. The firm has a market capitalization of $296.40 billion, a P/E ratio of 45.44, a PEG ratio of 2.06 and a beta of 0.40. The company has a debt-to-equity ratio of 1.60, a quick ratio of 0.98 and a current ratio of 1.27. The firm’s 50 day moving average price is $297.48 and its two-hundred day moving average price is $274.96. Eli Lilly and Company has a 52 week low of $217.00 and a 52 week high of $324.08.

Eli Lilly and (NYSE:LLYGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.62 EPS for the quarter, topping the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. Eli Lilly and’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.87 EPS. Analysts expect that Eli Lilly and Company will post 8.27 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Monday, May 16th were issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 1.26%. The ex-dividend date was Friday, May 13th. Eli Lilly and’s payout ratio is 58.07%.

Several hedge funds have recently made changes to their positions in the stock. Cordant Inc. acquired a new stake in Eli Lilly and in the 1st quarter worth about $25,000. AllSquare Wealth Management LLC acquired a new stake in Eli Lilly and in the 4th quarter worth about $28,000. HWG Holdings LP acquired a new stake in Eli Lilly and in the 4th quarter worth about $28,000. Icapital Wealth LLC acquired a new stake in Eli Lilly and in the 1st quarter worth about $28,000. Finally, Leverty Financial Group LLC acquired a new stake in Eli Lilly and in the 4th quarter worth about $29,000. 82.75% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on the stock. Daiwa Capital Markets assumed coverage on shares of Eli Lilly and in a report on Thursday, March 10th. They set an “outperform” rating and a $286.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. Wells Fargo & Company raised their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a report on Friday, April 29th. StockNews.com lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, Morgan Stanley lifted their price target on shares of Eli Lilly and from $364.00 to $369.00 in a research note on Friday, April 29th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and currently has an average rating of “Moderate Buy” and a consensus target price of $311.00.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.